These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32452085)

  • 1. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.
    Rossignol P; Williams B; Mayo MR; Warren S; Arthur S; Ackourey G; White WB; Agarwal R
    Eur J Heart Fail; 2020 Aug; 22(8):1462-1471. PubMed ID: 32452085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
    Agarwal R; Rossignol P; Romero A; Garza D; Mayo MR; Warren S; Ma J; White WB; Williams B
    Lancet; 2019 Oct; 394(10208):1540-1550. PubMed ID: 31533906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
    Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B
    Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial.
    Agarwal R; Rossignol P; Budden J; Mayo MR; Arthur S; Williams B; White WB
    Kidney360; 2021 Mar; 2(3):425-434. PubMed ID: 35369022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
    Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
    Pitt B; Anker SD; Bushinsky DA; Kitzman DW; Zannad F; Huang IZ;
    Eur Heart J; 2011 Apr; 32(7):820-8. PubMed ID: 21208974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
    Agarwal R; Pitt B; Palmer BF; Kovesdy CP; Burgess E; Filippatos G; Małyszko J; Ruilope LM; Rossignol P; Rossing P; Pecoits-Filho R; Anker SD; Joseph A; Lawatscheck R; Wilson D; Gebel M; Bakris GL
    Clin Kidney J; 2023 Feb; 16(2):293-302. PubMed ID: 36864892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of Patiromer Use: a Review.
    Ali W; Bakris G
    Curr Cardiol Rep; 2020 Jul; 22(9):94. PubMed ID: 32648072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH; Peters CD; Christensen JH; Birn H
    BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patiromer: A Review in Hyperkalaemia.
    Blair HA
    Clin Drug Investig; 2018 Aug; 38(8):785-794. PubMed ID: 30030701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
    BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
    Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes.
    Agarwal R; Rossignol P; Mayo MR; Conrad A; Arthur S; Williams B; White WB
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1407-1409. PubMed ID: 34162695
    [No Abstract]   [Full Text] [Related]  

  • 20. Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda.
    Georgianos PI; Agarwal R
    Curr Hypertens Rep; 2020 Sep; 22(10):84. PubMed ID: 32880742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.